Subtype
Lung Non-Squamous Non-Small Cell Carcinoma
CI-CAN-00005826Explore in graph →
93 active trials5 approved drugs127 evidence items
- NCIt
- C135017
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005826Explore in graph →
Clinical trials
408 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (55)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00776698 | A Study of Avastin (Bevacizumab) in Combination With Thoracic Radiation and Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer. | completed | Phase 1 | 1 | Hoffmann-La RocheINDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT00806923 | A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 1,044 | Hoffmann-La RocheINDUSTRY | 20 | Nov 2, 2016 | clinicaltrials |
| NCT00975182 | A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors | completed | Phase 1 | 58 | Genentech, Inc.INDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT01070927 | An Exploratory Study of RO4929097 in Patients With Recurrent or Refractory Non-Small Cell Lung Cancer | completed | Phase 2 | 7 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01194050 | An Observational Study of Tarceva (Erlotinib) in Routine Practice For First Line Maintenance Therapy in Patients With Non Small Cell Lung Cancer | completed | — | 289 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01333007 | An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer | completed | — | 423 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01343914 | An Observational Study on Patients With Non-Squamous NSCLC Who Reached A Long PFS After Avastin (Bevacizumab)-Based First-Line Therapy | completed | — | 118 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01488331 | An Observational Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer | completed | — | 217 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01659970 | PEPITA Study: An Observational Study of Tarceva (Erlotinib) in Second Line in Patients With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer | completed | — | 152 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01790217 | An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (GERTAC) | completed | — | 52 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01496742 | A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer | completed | Phase 2 | 259 | Genentech, Inc.INDUSTRY | 13 | Sep 23, 2016 | clinicaltrials |
| NCT01519804 | A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer | completed | Phase 2 | 108 | Genentech, Inc.INDUSTRY | 9 | Sep 2, 2016 | clinicaltrials |
| NCT01066884 | A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 4 | 5 | Hoffmann-La RocheINDUSTRY | 1 | Aug 24, 2016 | clinicaltrials |
| NCT02774278 | A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC)(MERIT) | completed | Phase 2 | 264 | Hoffmann-La RocheINDUSTRY | 14 | Aug 8, 2016 | clinicaltrials |
| NCT00451906 | A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer. | completed | Phase 4 | 2,252 | Hoffmann-La RocheINDUSTRY | 40 | May 24, 2016 | clinicaltrials |
| NCT00642473 | A Study of Metronidazole Cream in the Prevention and Treatment of Tarceva (Erlotinib)-Associated Rash(MATER) | completed | Phase 2 | 34 | Hoffmann-La RocheINDUSTRY | 1 | May 23, 2016 | clinicaltrials |
| NCT00518011 | A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer. | completed | Phase 2 | 17 | Hoffmann-La RocheINDUSTRY | 1 | May 16, 2016 | clinicaltrials |
| NCT02596958 | Safety and Efficacy Study of Avastin in Locally Advanced Metastatic or Recurrent Non-small Lung Cancer (NSLC) Participants | completed | — | 996 | Hoffmann-La RocheINDUSTRY | 1 | Apr 4, 2016 | clinicaltrials |
| NCT00976456 | Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer(65plus) | completed | Phase 3 | 271 | PD Dr. med. Wolfgang SchuetteOTHER | 1 | Mar 10, 2016 | clinicaltrials |
| NCT00961415 | AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer | completed | Phase 3 | 376 | Hoffmann-La RocheINDUSTRY | 12 | Feb 22, 2016 | clinicaltrials |
| NCT01372384 | A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations | completed | Phase 2 | 6 | Hoffmann-La RocheINDUSTRY | 1 | Feb 2, 2016 | clinicaltrials |
| NCT01609543 | A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations | completed | Phase 4 | 62 | Hoffmann-La RocheINDUSTRY | 3 | Feb 1, 2016 | clinicaltrials |
| NCT01185847 | A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 | 90 | Hoffmann-La RocheINDUSTRY | 7 | Jan 1, 2016 | clinicaltrials |
| NCT01664533 | An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy(TIME) | completed | — | 57 | Hoffmann-La RocheINDUSTRY | 1 | Dec 28, 2015 | clinicaltrials |
| NCT00883779 | A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer | completed | Phase 3 | 451 | Hoffmann-La RocheINDUSTRY | 7 | Dec 14, 2015 | clinicaltrials |
| NCT01204697 | A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN) | completed | Phase 2 | 74 | Hoffmann-La RocheINDUSTRY | 1 | Nov 16, 2015 | clinicaltrials |
| NCT01535729 | An Observational Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer | completed | — | 465 | Hoffmann-La RocheINDUSTRY | 1 | Oct 29, 2015 | clinicaltrials |
| NCT01077713 | A Study of Avastin (Bevacizumab) in Combination With Gemcitabine With or Without Cisplatin in First-Line Treatment of Elderly Patients With Non-Small Cell Lung Cancer | completed | Phase 2 | 86 | Hoffmann-La RocheINDUSTRY | 1 | Oct 8, 2015 | clinicaltrials |
| NCT00368992 | S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 110 | National Cancer Institute (NCI)NIH | 1 | Sep 14, 2015 | clinicaltrials |
| NCT01204307 | Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation | completed | Phase 2 | 101 | Chang Gung Memorial HospitalOTHER | 1 | Jul 28, 2015 | clinicaltrials |
| NCT00716456 | Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib | completed | Phase 1 / Phase 2 | 21 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00511485 | Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03) | completed | Phase 2 | 43 | EndocyteINDUSTRY | 0 | Feb 27, 2015 | clinicaltrials |
| NCT00384826 | Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma | completed | Phase 2 | 133 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Feb 16, 2015 | clinicaltrials |
| NCT01578668 | Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases | completed | Phase 2 | 69 | Guangzhou Medical UniversityOTHER | 1 | Jan 26, 2015 | clinicaltrials |
| NCT00049543 | Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery | completed | Phase 3 | 503 | National Cancer Institute (NCI)NIH | 1 | Jan 1, 2015 | clinicaltrials |
| NCT00118144 | Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2014 | clinicaltrials |
| NCT01668823 | Photodynamic Therapy in Treating Patients With Lung Cancer | completed | Phase 1 | 17 | Roswell Park Cancer InstituteOTHER | 1 | Jul 31, 2014 | clinicaltrials |
| NCT01561456 | Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung | completed | Phase 2 | 100 | Axelar ABINDUSTRY | 5 | Dec 5, 2013 | clinicaltrials |
| NCT00002852 | Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer | completed | Phase 3 | 500 | National Cancer Institute (NCI)NIH | 1 | Jul 3, 2013 | clinicaltrials |
| NCT00040794 | Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer | completed | Phase 2 | 144 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00118183 | Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 62 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00029003 | Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Nov 2, 2016source: clinicaltrials